Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma

Drug resistance remains the key problem in cancer treatment. It is now accepted that each myeloma patient harbors multiple subclones and subclone dominance may change over time. The coexistence of multiple subclones with high or low chromosomal instability (CIN) signature causes heterogeneity and dr...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Invest
Autori principali: Franqui-Machin, Reinaldo, Hao, Mu, Bai, Hua, Gu, Zhimin, Zhan, Xin, Habelhah, Hasem, Jethava, Yogesh, Qiu, Lugui, Frech, Ivana, Tricot, Guido, Zhan, Fenghuang
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society for Clinical Investigation 2018
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6026005/
https://ncbi.nlm.nih.gov/pubmed/29863498
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI98765
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi